AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 162 min read$JSPR

Jasper Therapeutics Appoints Regulatory, Clinical Executives For Pipeline Development; Stock Up

Jasper Therapeutics (JSPR) appointed Lisa Pitt and Shiguang Liu to key regulatory and clinical roles. The company reported a Q2 2026 net loss of $2.76M and has $7.3M in cash. It plans FDA meetings for KP-104 and Briquilimab in 2027. JSPR stock is up 5.24% in after-hours trading.

Original reporting
rttnews.com
Published Sep 16, 2026, 7:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$JSPR
Neutral
medium confidence
Mentioned
$JSPR
Relevance
5/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$JSPRNeutralLow
01

Why it matters

The appointments aim to strengthen regulatory and clinical development capabilities ahead of FDA interactions in 2027.

02

Market read

Exec hires and option grants are modest news for a micro‑cap biotech, offering limited trading impetus.

03

What to watch

Potential upcoming FDA meetings for pipeline candidates could become catalysts later.

Relevance 5/10Novelty 5/10Timing: after-hours Tuesday

Background

Jasper Therapeutics is a clinical‑stage biotech focusing on immune‑mediated diseases with a cash position of $7.3 M.

Company-level read

Ticker impact

$JSPRNeutralMedium confidence
Context

Jasper Therapeutics announced senior regulatory and clinical executive appointments and granted stock options to new employees.

Expected impact

Potential slight upside if milestones are met, but limited immediate price move.

Evidence & confidence

New leadership could enhance pipeline progress, yet no concrete milestones or financial impact disclosed.

Market effects

Sector

May signal continued talent acquisition in biotech sector, but limited broader impact.

Regional

Primarily U.S. micro‑cap biotech market; no regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

Executive hires rarely translate to short‑term price gains; investors may remain cautious.

Key entities

  • Executive
    Lisa Pitt

    Senior Vice President, Regulatory Affairs

  • Executive
    Shiguang Liu

    Vice President, Clinical Development

Read at source← All news

Related articles

AUG 17
$JSPRMed

Jasper Therapeutics beats Q2 expectations but shares fall after results

Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2026 adjusted loss of $0.10 per share, better than the $0.28 consensus, and a net loss of $2.8 million. Shares fell 4.24% pre-market. In July, Jasper completed an all-stock acquisition of Kira Pharmaceuticals and a $132 million private placement, extending its funding runway into 2H 2028. Pipeline updates include KP-104 Phase 2 interim data in Q4 2026 and briquilimab and KP-701 milestones in early 2027.

yahoo.com4 min
AUG 14
$JSPRMed

Jasper Therapeutics, Inc. (JSPR): Results of Operations and Financial Condition

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders

SEC EDGAR 8-K6 min
AUG 14
$JSPRMedAI 8/10

Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline

Jasper Therapeutics (JSPR) reported Q2 2026 results and a corporate update after completing its all-stock acquisition of Kira Pharmaceuticals on July 16, 2026. The company raised about $132M via a private placement of non-voting convertible preferred stock. Cash was $7.3M at June 30. Net loss was $2.8M. Pipeline updates include KP-104, briquilimab, and KP-701.

rttnews.com6 min
JUL 20
$JSPRMedAI 9/10

Jasper Therapeutics merges with Kira Pharmaceuticals

Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, forming a combined Nasdaq-listed company under ticker JSPR. The deal includes a $132M private placement and a $12M Mirador out-licensing payment on signing, funding operations through H2 2028. Pipeline includes KP-104, briquilimab, and KP-701 with upcoming clinical milestones.

pharmatimes.com5 min
JUL 17
$JSPRMedAI 8/10

Jasper Closes Kira Deal, Extends Cash Runway - Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics (NASDAQ:JSPR) closed a deal with Kira and completed a private placement of non-voting convertible preferred stock raising about $132 million gross. The company expects cash to fund operations through 2H 2028. Jasper out-licensed Kira’s KP-301 and KP-402 to Mirador for $12 million upfront plus milestones. JSPR shares rose 20.67% to $0.9250.

benzinga.com5 min
JUL 17
$JSPRMed

Jasper Therapeutics, Inc. (JSPR): Completion of Acquisition or Disposition of Assets

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ea029822901ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED JULY 16, 2026, BY AND AMONG JASPER THERAPEUTICS, INC., KIRA HOLDCO INC. AND KIRA PHARMACEUTICALS Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: JASPER THERAPEUTICS, INC., a Delaware corporation; KIRA HOLDCO INC.,

SEC EDGAR 8-K6 min